Animalcare has announced the UK and Ireland launch of Vitofyllin, a central nervous system stimulant for older dogs suffering from dullness, poor demeanour and unwillingness to exercise.

The launch of Vitofyllin is the result of a collaboration between Animalcare and three European partners.

The company says the project has enhanced its in-house expertise because the active ingredient for the product was unavailable in the market and had to be contract synthesised, a first for a new product development at Animalcare. The regulatory procedure was also the first time a bioequivalence bio-waiver had been successfully applied for and obtained in Europe. This made the development quicker, more cost effective, less risky and importantly avoided the need for animal testing.

Animalcare says that as in previous years, it has set itself a target of launching four new veterinary medicines during the year. This launch is the first of those planned for the new financial year.

Stephen Wildridge, CEO of Animalcare Group, said: "We are very pleased to be able to add our new generic medicine Vitofyllin to our range of licensed veterinary medicines. The launch represents the culmination of the biggest development project undertaken by Animalcare and is the product of successful collaboration with members of our European partnership network."

Virbac Animal Health is offering a client e-shot and text alert service for practices taking part in its Canine Prostate Awareness Month initiative this year.

Canine Prostate Awareness Month takes place during November 2012 following its debut last year when more than 400 practices signed up to support it.

Timed to coincide with 'Movember' when thousands of men grow moustaches to raise funds for male prostate and testicular cancer, Canine Prostate Awareness Month aims to highlight the prevalence of the disease in dogs and to encourage practices and owners to test for it. In addition to the new e-shot and text alert service, Virbac already provides post card reminders; free dog leads; educational and display materials and a press release for use by practices with their local media.

Participating practices that diagnose a dog with Benign Prostatic Hyperplasia during Canine Prostate Awareness Month are being asked to contact Virbac with details, as the company plans to collate a series of case studies from the initiative this year. The five best cases studies submitted before the end of the year will win Love2Shop vouchers to the value of £50.

Chris Geddes MRCVS, Virbac Product Manager, said: "There's a lot of interest already in this year's Canine Prostate Awareness Month so we're working hard to ensure it's even bigger and better than last year.

The serious message is that more than 80% of entire male dogs over the age of five suffer from Benign Prostatic Hyperplasia¹.  Canine Prostate Awareness Month gives practices a reason to highlight the risk and encourage owners to test for it. Timing Canine Prostate Awareness Month to coincide with Movember is a good way to interest dog owners at a time when some might be considering the state of their own prostate."

For further information on Canine Prostate Awareness Month, email cpam@virbac.co.uk; contact your Virbac Territory Manager or contact the company direct on 01359 243243.

Reference

1.    O'Shea J.D. Studies on the canine prostate gland: Factors influencing its size and weight. J. Comp. Pathol. 1962 72: 321-331.

The Royal College of Veterinary Surgeons Charitable Trust has awarded five new bursaries in its latest grants round.

Two student bursaries were for UK veterinary undergraduates to attend the British Science Festival in Aberdeen from 4-9 September 2012. The bursary winners were Liv Nathan (pictured on right), a third-year veterinary student at the Royal Dick School of Veterinary Studies, and Alahel Mahdmina, a second-year veterinary student at the Royal Veterinary College.

Liv said: "I am very enthusiastic about providing real-life context to science and giving people a space to consider issues arising around science."

The students were required to use their observations and experiences to help the Trust develop future outreach activities to inform and inspire public audiences about veterinary clinical practice and research. Their bursary packages covered all their attendance expenses over the four-day event. One of their achievements was to film an interview with Dr Maggie Aderin-Pockock MBE, a space scientist (pictured on left). Both students will be reporting back in full to the RCVS Charitable Trust with their ideas at the end of October. 

Two further bursaries were given to attend  a joint symposium on antimicrobial resistance (AMR): 'Antimicrobial Resistance in Human and Veterinary Medicine - One Health, One Problem' to be held at the Royal College of Physicians, London, on Tuesday 2 October 2012. 

One winner was Cahir King, a practitioner from Downe Veterinary Clinic in County Down, Northern Ireland.  He said: "It will be a privilege to attend a symposium at which so many experts in their field will be speaking.  Any vet who has worked on farms will be more than familiar with bugs that are resistant to antibiotic treatment."

The other winner was James Swann, a Junior Clinical Training Scholar (Small Animal) at the Royal Veterinary College. James said: "I am particularly interested in the application of clinical audit in practice to assess problems like AMR, and design effective strategies to deal with them. I believe it should be possible to provide simple audit kits for practices to download and implement, removing much of the inertia that prevents such ideas from being initiated."

The bursary winners will be offered free delegate passes, including lunch, worth £90, and travel expenses.

The final bursary is to attend the Veterinary Biomedical and Pharma Sciences (VBMPS) Congress on 15-16 October, in Birmingham.

The winning entry was from Alexander Stoll, a final-year student at the Royal Veterinary College, who acted as the Royal Veterinary College and  UK student ambassador to the European Commission for the 'One Health' message. The Trust was impressed with Alexander's enthusiasm and active engagement in subjects related to One Health.  He is a member of the Royal Society for Public Health and a member of the Society of Biology.

Alexander said: "I hope to be inspired to enter a cross-disciplinary career path and also to communicate the potential of a One Health approach, inspired by this congress."

Alexander won a package that includes entry to the conference and admission to all scientific sessions, worth £175, as well as transport costs and overnight food and accommodation.

Petplan Equine has announced the finalists for the fifth annual Petplan Equine Vet of the Year Award.

The winner of the award award, which is sponsored by Petplan Equine in association with Horse & Rider magazine, will be announced at the annual Animal Health Trust Equestrian Awards, being held at London's Lancaster Hotel on Thursday 1^st November, 2012.

The finalists are:

Jess Hill BVM&S MRCVS Woodlands Veterinary Clinic, Cheltenham, Glos, England
Jess, who qualified in 2003 at the University of Edinburgh Royal (Dick) School for Veterinary Studies, is described as simply "brilliant" for her outstanding calm, capable and kind approach to her work and the way in which she makes herself readily available to her clients.  One nomination typifies all those received in praise of Jess' work: "She is incredibly knowledgeable and dedicated and nothing is too much trouble. She is great with horses - always quiet, kind and gentle. She works quickly and confidently, doesn't suggest unnecessary expensive procedures and is always cheerful and a pleasure to be with."

Keith Chandler BVMS Cert EP MRCVS, Kessock Equine Vets, Inverness, Scotland
Keith Chandler, a senior partner at Kessock Equine Vets received several nominations which credited not only him personally for his dedication, knowledge, pragmatic and caring approach but also his practice for its outstanding customer service. Upon receiving news of his nomination, Keith was swift to praise his team and explained: "This nomination reflects the exceptional team I have around me - together we strive to offer continuity, consistency and a minimum level of care to all our clients irrespective of which vet is in attendance."

Lee Paul, BSC BVM&S Cert EP MRCVS, Bushy Equine, Gwaelod-y-Garth, Wales
Nominations for Lee Paul, a specialist in internal and stud medicine who qualified at Edinburgh University's Royal Dick Veterinary School in 2002, unanimously praised his willingness to 'never give up' and to go beyond the call of duty. He is said to be highly dedicated and is praised for his willingness to always be available such as on the occasion when a horse he had been treating for a swelling in her throat presented complications during a weekend when he was not on duty. Despite this Lee, who had been contacted by the duty vet for background information, attended the call himself within an hour complete with the stethoscope he'd collected from the surgery en route and with his family in his car!

This year's judges were David Stickles, Head of Fund Raising at the Animal Health Trust, Alison Bridge, Editor of Horse & Rider magazine, Ben Mayes, President of the British Equine Veterinary Association (BEVA) and Gil Riley, 2009 Petplan Equine Vet of the Year.

Petplan says that the record number of high calibre nominations made it hard for the judges to choose three finalists. Isabella Von Mesterhazy, Head of Marketing for Petplan Equine said: "Anyone motivated to nominate their vet for this award must hold them in extremely high regard so once again we were very impressed by both the quality and quantity of nominations we received. It is heartwarming and inspiring to read the submissions that describe the outstanding contributions made by all the nominees in keeping owners happy and horses healthy. It has not been easy to select just three to go through to the final."

The winner will be posted on www.petplanequine.co.uk on Friday 2 of November.

Petplan has announced that it has raised £1million for the Blue Cross in the past decade.

The funds have gone towards running a dozen rehoming centres for dogs, cats, horses and rabbits, as well as four major animal hospitals across the country.

Petplan offers four weeks free insurance to adopters of dogs, cats and rabbits from Blue Cross as well as many other animal charities across the UK. All animal charities who work with Petplan receive 10% of the premium for any full policies they generate. The company says that in 2011, it raised over £2million for animal charities this way.

Petplan says that in addition to creating additional funds for the charity, providing four weeks free pet insurance also gives charities peace of mind that if the pet should require veterinary treatment the adopter has the funds available to ensure the animal receives the care it needs. This also means that the animal is less likely to be returned to the charity because the adopter can't afford the veterinary fees or that the charity will be asked to help cover the cost of treatment.

Chief Executive of the Blue Cross, Kim Hamilton, said: "As a charity that does not receive any government or lottery funding, we rely solely on donations from the public and valuable funding from our corporate partners. Petplan understands that our primary focus is animal welfare and the income generated from working with them has enabled us to give even more pets a healthy life in a happy home."

Simon Masding, Petplan's Head of Sales and Partnerships said: "At Petplan we work with over 1,700 animal charities and therefore understand the financial struggles that charities face on a daily basis. Along with offering charities commission Petplan also run the Charity Cheque initiative. When a four weeks free pet insurance voucher is activated it automatically enters the charity into a monthly prize draw to win £500."

For more information on how your animal charity can work with Petplan please visit www.petplan.co.uk/charity or call Charityline on 0800 072 8877. 

Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.

Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases." 

Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.

Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."

For further product information, visit www.norbrook.com

The BVA has announced that from 2013, its annual Congress will take place at the London Vet Show.

The association says that the move is being done to bring together political debate and clinical CPD on a large scale and to ensure that the BVA can reach an even wider audience with its representative and educational services.

The BVA and the Vet Show teamed up last year at London Vet Show 2011 to announce the launch of the BVA Careers Fair, which will be hosted at this year's London Vet Show on 15-16 November, and the start of a partnership that would ensure discounted Vet Show rates for BVA members.

2013 will also see two new clinical streams added to the London Vet Show programme creating a comprehensive CPD event for vets in small and mixed practice. Cattle and equine streams for mixed practitioners will be delivered by the BVA to run alongside the popular companion animal stream provided by the Royal Veterinary College.

The partnership will also see substantial discounts being offered to BVA members.

BVA President Carl Padgett said: "BVA's number one value is that our members are at the heart of everything we do. We know that members require good value, high quality and relevant CPD and we believe that our new partnership with the London Vet Show offers the best opportunity for us to provide members with exactly what they want.

"It's a significant move for BVA but one that makes complete sense. From 2013 we will be bringing together the contentious issue streams that are the bedrock of BVA Congress, with a high quality clinical CPD programme covering large and small animals, and one of the biggest and best veterinary exhibitions.

"We know we haven't attracted the delegate numbers we would like to have done in recent years and by partnering with the London Vet Show we have the opportunity to reach a much greater audience. It's a very exciting step forward for BVA."

Rob Chapman, Event Director for the London Vet Show, said: "We are all delighted to be developing our relationship with the BVA. To be able to host such an established and prestigious event as the BVA Congress at the London Vet Show is an honour for the Vet Show.

"Combining the long-standing history of the BVA with the rapidly developing reputation of the Vet Show gives us a great symbiotic relationship. The new clinical content that we will be working on together will help the event and that relationship even further offering great value for both Vet Show delegates and BVA members."

Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.

The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.

According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.

The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.

The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.

Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.

"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."

The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.

In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.

A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.

On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb. 

In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.

* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.

The Feline Advisory Bureau (FAB) has teamed up with Agria Pet Insurance to provide insurance cover for cats in the UK, with each policy generating a donation to the work of FAB and its International Fund for Cat Welfare.

Ross Tiffin, FAB's Strategy and Business Adviser said: 'In Agria, we have found a respected company that shares our ethos - it believes in sharing information to makes cats' lives better. One of the leading pet insurers in the world, Agria has been insuring pets since 1890 and has shared information on longevity and disease patterns with university researchers for many years.'

Claire Bessant, Chief Executive of FAB said: 'FAB has always been an enthusiastic supporter of health insurance for cats - we want cats to receive the best treatment without owners having to worry about the cost. Our support has now taken on a practical form in the shape of a general pet insurance guide and, through working closely with Agria, by providing cat owners with an excellent insurance option.'

To view A fabcats guide to cat insurance go to www.fabcats.org/catinsurance. The guide gives generic advice on choosing insurance.

For more information on Fabcats Cat Insurance from Agria go to www.fabcats.org/catinsurance or call Agria on 0800 369 9441.

Dorwest Herbs has launched its annual 'Dorwest Say Relax' fireworks phobia campaign, which includes free promotional packs for practices.

The promotional packs, which contain a poster, leaflets, flashing badges and a 'Dorwest Say Relax' t-shirt, being given free to the first 100 practices that request a product box (containing licensed Scullcap & Valerian Tablets and Organic Valerian Compound at a discounted price) from the company.

In addition, Dorwest is running a seemingly popular consumer facebook competition to find the most relaxed dog in the nation, the winner of which will be sent on a pet-friendly luxury weekend break.

Finally, the company is writing a blog written from the perspective of Merlin, the dog used in its logo - http://merlintakescontrol.wordpress.com - though quite who is going to read it, or why, is slightly beyond me.

Animalcare has released further information about Vitofyllin (propentofylline), its new CNS stimulant for dogs.

According to the company, Vitofyllin helps restore vitality and willingness to exercise, especially in the senior dog, by improving peripheral and cerebral vascular blood circulation. It is indicated to help improve dullness, lethargy and overall demeanour in dogs. In addition it has a bronchodilatory activity equivalent to amilophylline (a salt of theophylline)

Animalcare says that with dogs living longer, age-related problems are on the increase. The company highlights the example of Cognitive Dysfunction Syndrome (CDS), a neurodegenerative disease that affects older dogs. CDS is characterised by various pathological processes with signs that include disorientation, changing interaction with people or other pets, sleep-wake cycle alterations, soiling in the house and decreased activity levels.

The company says these subtle behavioural changes are unlikely to be picked up at a routine annual check. Indeed, in one study 75% of owners of dogs aged over 7 reported at least one behavioural sign consistent with CDS, however only 12% reported their concerns to a vet.²

Vitofyllin is available in 50mg and 100mg strengths in blister packs containing 56 tablets. Presented as 'easy to administer' four-way split cross-snap-tabs which can be divided into halves or quarters to enable more accurate dosing to be achieved whatever the weight of animal, even down to 2.5kg bodyweight.

Vitofyllin is POM-V licensed and has a 3 year shelf-life. Waiting room posters and client leaflets are available to support recognition of behavioural signs by clients and practice staff.

Further iinformation, and details about a special launch offer are available from local Animalcare representatives.

Reference

• Landsberg G and Araujo JA., Behaviour problems in geriatric pets. Veterinary Clinics Small Animal Practice (2005),35:675-698

The BVA has welcomed the decision to prohibit the advertising of antimicrobials directly to animal keepers from 2013 in a bid to reduce antimicrobial resistance.

The Veterinary Medicines Directorate (VMD) announced that the Veterinary Medicines Regulations will be revised next year. The change has come as a result of the European Commission's view that the UK did not correctly transpose the European Directive 2001/82/EC which prohibits the advertising of certain veterinary medicinal products to the 'general public'.

When the VMD consulted on proposals to restrict the advertising of antimicrobials to farmers in 2010 the BVA supported the measure as a sensible approach to the responsible use of antimicrobials.

In a letter to stakeholders the VMD explained that: "A number of interested parties from veterinary medicine hold the view that the advertising of antibiotics to keepers of animals leads to undue pressure to prescribe newer antibiotics, which can often be important in human medicine and are associated with the development of multiple resistances."

Peter Jones, President of the BVA, said: "The BVA has consistently argued for the restriction of advertising of antimicrobials to animal keepers and we believe this is the right decision.

"New antimicrobials are heavily advertised by pharmaceutical companies and there can be undue pressure put on veterinary surgeons by clients who want to try new products that promise good results, but which may not be appropriate from the point of view of responsible use.

"Antimicrobial resistance is a very serious issue for both animal and human health and we are pleased that the European Commission and the VMD have taken the view that the Regulations need to be revised.

"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets will continue to work with their farm clients to ensure antimicrobials are used prudently and responsibly."